Avidity Biosciences News and Activities

Presence

Avidity Biosciences develops RNA-based medicines for rare muscle and neuromuscular diseases. Its products and services include drug research, clinical development, and therapeutic candidates for patients, healthcare providers, and research partners.

Avidity Biosciences products and services overview:

RNA therapies
Rare disease drugs
Clinical development
Drug discovery

Revenue: ~$5 million

Employees: 320

Headquarters: San Diego, United States (USA)

Avidity Biosciences is owned by Novartis.

Novartis is one of the...

Novartis is a company listed under the stock ticker NOVN (CH).

Novartis has a direct presence in 35 countries.

Novartis has 54 subsidiaries including Alcon, Alcon ANZ and Alcon APAC.

They are in:

Acquisition, funding and merger involving Novartis.

Novartis has acquired Avidity Biosciences (posted on March 3 2026).
Novartis has announced the acquisition of Avidity Biosciences (posted on October 27 2025).

Executives

View the org chart displaying its 26 main executives

Most searched biographies at Avidity Biosciences

Popular executive movements at Novartis

Liz Moran has joined the company as Vice President, Talent and Development (posted on May 31 2026).
Mukul Mehta, who was Head of Business and Digital Finance and Tax, is promoted to Chief Financial Officer (posted on March 18 2026).
Charles Swanton has joined the company as Director (posted on March 13 2026).

Click here to view some more movements at Novartis

Create your alert
to follow the executive moves at Avidity Biosciences.